These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7962541)

  • 1. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.
    Tang YW; Graham BS
    J Clin Invest; 1994 Nov; 94(5):1953-8. PubMed ID: 7962541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine pattern is solely influenced by priming vaccine but immunity and disease by both priming and boosting vaccines in mice challenged with respiratory syncytial virus.
    Tang YW
    Virus Res; 2004 Jan; 99(1):81-7. PubMed ID: 14687950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
    J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.
    Tang YW; Graham BS
    J Clin Invest; 1997 May; 99(9):2183-91. PubMed ID: 9151790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity.
    Tang YW; Graham BS
    J Infect Dis; 1995 Sep; 172(3):734-8. PubMed ID: 7658066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.
    Graham BS; Henderson GS; Tang YW; Lu X; Neuzil KM; Colley DG
    J Immunol; 1993 Aug; 151(4):2032-40. PubMed ID: 8345194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern.
    Waris ME; Tsou C; Erdman DD; Zaki SR; Anderson LJ
    J Virol; 1996 May; 70(5):2852-60. PubMed ID: 8627759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse.
    Tripp RA; Jones L; Anderson LJ; Brown MP
    J Immunol; 2000 Jun; 164(11):5913-21. PubMed ID: 10820273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo.
    Aung S; Tang YW; Graham BS
    J Virol; 1999 Nov; 73(11):8944-9. PubMed ID: 10515999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte activity and cytokine expression in calves vaccinated with formalin-inactivated bovine respiratory syncytial virus prior to challenge.
    Woolums AR; Gunther RA; McArthur-Vaughan K; Anderson ML; Omlor A; Boyle GA; Friebertshauser KE; McInturff PS; Gershwin LJ
    Comp Immunol Microbiol Infect Dis; 2004 Jan; 27(1):57-74. PubMed ID: 14656542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
    Osorio Y; Ghiasi H
    J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.
    Martinez X; Li X; Kovarik J; Klein M; Lambert PH; Siegrist CA
    Eur J Immunol; 1999 Oct; 29(10):3390-400. PubMed ID: 10540351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection.
    Dodd JS; Lum E; Goulding J; Muir R; Van Snick J; Openshaw PJ
    J Immunol; 2009 Dec; 183(11):7006-13. PubMed ID: 19915054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.
    Tripp RA; Anderson LJ
    J Virol; 1998 Nov; 72(11):8971-5. PubMed ID: 9765442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.